NYSE$STVN
Stevanato Group S.p.A. · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Stevanato tops Q3 views as high-value syringes drive BDS growth and margins expand
Stevanato Group reported third-quarter 2025 revenue of €303.2 million, up 9% year over year (11% constant currency), beating expectations as roughly €10 million of Biopharmaceutical & Diagnostic Solutions shipments pulled forward from Q4. BDS revenue rose 14% to €266.7 million on a 47% jump in high-value solutions, while Engineering fell 19% to €36.4 million amid slower order conversion. Adjusted operating margin expanded 220 bps to 18.5% and adjusted EBITDA reached €77.8 million (25.7% margin). Net profit was €36.1 million (€0.13 diluted EPS; adjusted EPS €0.14). Management reaffirmed full-year revenue guidance of €1.16–1.19 billion with adjusted EBITDA of €288.5–301.8 million.
- Revenue grew 9% to €303.2M with BDS up 14% to €266.7M, helped by ~€10M of shipments pulled into Q3 from Q4
- High-value solutions surged 47% to €147.9M and reached 55% of BDS revenue; adjusted EBITDA margin improved 280 bps to 25.7%
- Engineering revenue fell 19% to €36.4M as glass conversion and assembly line demand remained soft
- Net profit totaled €36.1M (adjusted €38.5M); adjusted diluted EPS rose 17% to €0.14
- FY25 guidance maintained: revenue €1.160–1.190B, adjusted EBITDA €288.5–301.8M, adjusted EPS €0.50–0.54
Headline financials
Revenue & EPS history
Stevanato Group · Revenue · Quarterly
€303M
Revenue by segment
Stevanato Group · €303M total across 2 segments · Q3 2025
- Biopharmaceutical and Diagnostic Solutions€267M—88.0%
- Engineering€36.4M—12.0%
Forward guidance
Full-year 2025 guidance unchanged: revenue €1.160–1.190 billion, adjusted EBITDA €288.5–301.8 million, and adjusted diluted EPS €0.50–0.54, with high-value solutions now expected at 43–44% of total revenue.
Tailwinds
- High-value solutions mix trending above prior 40–42% assumption
- BDS momentum and margin expansion support FY targets
Headwinds
- Engineering segment recovery taking longer than anticipated
- FX translation headwind widened to ~€15–16M for the full year
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2025
+1.4%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+3.0%
Avg return
30 days after
58%
11 / 19 earnings
Positive
+22.3%
Q2 2021
Best reaction
-18.9%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +10.0% | +1.9% | -10.3% | |
| Q3 2025 | -1.7% | -3.3% | -11.6% | |
| Q2 2025 | -9.6% | -7.6% | -9.9% | |
| Q1 2025 | +2.9% | +12.0% | +8.9% | |
| Q4 2024 | +8.6% | +8.8% | +10.5% | |
| Q3 2024 | +16.4% | +12.4% | +3.9% | |
| Q2 2024 | +4.4% | +8.5% | +13.8% | |
| Q1 2024 | -18.9% | -20.7% | -30.8% | |
| Q4 2023 | -11.3% | -14.1% | -12.4% | |
| Q3 2023 | -5.9% | -2.5% | -3.5% | |
| Q2 2023 | +2.5% | +5.6% | +6.3% | |
| Q1 2023 | -3.3% | -1.5% | +2.6% | |
| Q4 2022 | +13.7% | +5.2% | +16.0% | |
| Q3 2022 | +0.4% | +9.1% | +18.0% | |
| Q2 2022 | +4.6% | -3.4% | -5.9% | |
| Q1 2022 | +0.7% | +8.7% | +11.2% | |
| Q4 2021 | -1.4% | -4.2% | +21.9% | |
| Q3 2021 | -8.7% | -11.2% | -4.8% | |
| Q2 2021 | +22.3% | +27.0% | +33.8% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro